Cepheid VP sells off company shares; Three Dx tests shine as screens for TB treatment resistance;

> Saladax Biomedical won health department licenses from California, Rhode Island and Maryland to expand MyCare diagnostic testing to gauge a person's optimal chemotherapy dose. Item   

> Cepheid ($CPHD) Vice President David Persing unloaded 20,000 shares of Cepheid stock on Sept. 6 and now directly owns 177 shares in the company. Story

> The first in-vitro diagnostics control laboratory in West Africa launched recently in Nigeria. Story

> Three rapid diagnostic tests show promise as an alternative to standard assays used to test for drug resistance in tuberculosis patients. Item

> Advanced Biological Laboratories in Luxembourg signed a collaboration deal with Roche Diagnostics International to promote ABL next-generation sequencing technology in Europe, the Middle East, Africa and Latin America. Item

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.